When: Confirmed close >$196.38 on >8M shares with RSI pushing through 60 and MACD histogram positive-expanding

Then: Size 0.5x normal notional

When: Q3 EPS ≥$2.30 with smoke-free mix >42% AND margin expansion

Then: Fresh adds permissible at $174-178 (200 SMA retest) or post-breakout >$200

HOLD the existing position. Do NOT add at current levels. Wait for confirmed breakout above 196.38 with volume and expanding MACD, or a controlled dip into 182-185 zone with momentum confirmation.

• Two failed tests at 194-195 resistance in nine sessions represents sellers defending the upside, not accumulation
• MACD histogram at 0.01 is unresolved momentum with no confirmation edge, described as a coin flip priced at the top of a range
• FDA PMTA streamlining remains news flow, not executed policy, with significant litigation risk from public health groups and state attorneys general
• Forward P/E of 20.76 paired with PEG of 2.28 represents a premium requiring everything to go right
• Negative book value of negative 8.58 billion dollars limits certain institutional buyers and distorts balance sheet metrics
• New annual dividend run-rate of approximately 9.98 billion dollars exceeds TTM free cash flow of 9.71 billion, resulting in sub-100% forward coverage
• Q4 2025 interest expense spiked to 839 million, creating cushion risk if operating cash flow disappoints
• Net debt is 43.11 billion with 97% probability of zero Fed cuts in 2026, representing higher-for-longer duration risk
• 3.36% dividend yield faces competition from 5.5% 10-year Treasury, limiting income thesis moat
• Scaling-in 1/3 position at 190 with stop at 186.29 exposes 2.4% of capital to insufficiently confirmed setup
• Consolidation pattern requires waiting for 50 SMA at 189.57 support tests or 196.38 breakout confirmation

→ vs aggressive: Sept 18's 7.81 million share session was flagged as absorption in the technical report but was actually the highest volume of the consolidation range that did NOT make a new high, representing textbook distribution rather than bullish demand entry

→ vs aggressive: FDA PMTA streamlining is treated as near-certain catalyst but remains Wall Street Journal news flow; actual reformed regulation must survive inevitable litigation from public health groups, state attorneys general, and competing industry players, with timing that could slip weeks or months

→ vs aggressive: 107% FCF coverage cited on TTM basis ignores that new quarterly dividend of 1.60 per share (6.40 annualized) creates a forward annual obligation of approximately 9.98 billion dollars against 9.71 billion in TTM free cash flow, resulting in sub-100% forward coverage with reduced cushion against negative surprises

→ vs aggressive: Forward P/E of 20.76 alone does not justify a growth multiple when PEG is 2.28, which represents a premium of more than 2x expected growth rate, and when negative book value of negative 8.58 billion creates balance sheet distortions that price-sensitive accounts monitor

→ vs aggressive: Scaling-in proposal of taking one-third position at 190 with stop at 186.29 increases dollar exposure to an uncertain outcome rather than providing asymmetry; correct discipline is waiting for histogram to actually turn positive and expanding before committing capital

HOLD existing position; take small starter position (10-15% of intended add) at current levels around 190 with stop at 186.29; reserve capital for second tranche entry at 182-185 on MACD histogram flat or positive; third tranche on confirmed breakout above 196.38 with volume above 8 million shares and RSI above 60.

• MACD histogram at 0.01 is unresolved and should not be treated as confirming bullish case
• Forward FCF coverage below 100% (9.98B dividend run-rate vs 9.71B TTM FCF) is a real risk the aggressive case underweights
• PEG of 2.28 represents a premium to growth, not a discount
• FDA PMTA announcement expected in coming days is a binary catalyst; chart will respond to announcement rather than precede it
• Smoke-free mix at 42% and rising is the structural story both other analysts underweighted
• Negative book value is an accounting artifact from aggressive buybacks, not a distress signal; ROA at 14.59% and operating margin at 40% are the relevant metrics
• Stable rate environment supports defensive dividend compounds; recession odds dropping from 12% to 8% is additional positive
• Three-tranche framework captures FDA catalyst exposure while limiting capital at risk to approximately 2.4% on starter position
• Trim 25-50% if 189.57 (50 SMA) breaks on volume; exit entirely if 182.71 fails on closing basis with measured move target at 167-170

→ vs aggressive: September 18 7.81 million share high-volume rejection at resistance is not confirmed absorption; requires assuming institutional accumulation without evidence

→ vs aggressive: 107% FCF coverage cited is TTM-based; forward coverage below 100% means dividend exceeds FCF generation at current run-rate, creating dividend sustainability risk

→ vs aggressive: Forward P/E at 20.76 may look reasonable but PEG at 2.28 is expensive by any framework; base case pricing assumes growth materializes with no buffer for estimate trimming

→ vs conservative: FDA PMTA announcement is expected imminently; waiting for chart confirmation means chart will confirm after the gap, not before; conservative entry at 182-185 may never fill if announcement is constructive

→ vs conservative: Negative book value is a technical accounting artifact from treasury stock (buybacks), not a distress signal; limits certain buyers but is not a thesis-breaker

→ vs conservative: 97% probability of no Fed cuts is supportive for defensive bond proxies with visible terminal rates, not a headwind; recession odds dropping to 8% is an additional positive for defensives that conservative case underweights